Bone disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:06:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bone disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Treating Adynamic Bone Disorder with Teriparatide in Patients with Chronic Kidney Disease https://clinicaltrials.eu/trial/study-on-treating-adynamic-bone-disorder-with-teriparatide-in-patients-with-chronic-kidney-disease/ Wed, 29 Apr 2026 14:23:51 +0000 https://clinicaltrials.eu/trial/study-on-treating-adynamic-bone-disorder-with-teriparatide-in-patients-with-chronic-kidney-disease/ This clinical trial is focused on studying the treatment of adynamic bone disorder in patients who have chronic kidney disease. The treatment being tested is a medication called teriparatide, which is given as a solution for injection under the skin. The main goal of the study is to see if 18 months of treatment with teriparatide can improve bone health better than no treatment at all in these patients.

Participants in the study will receive either the teriparatide treatment or no treatment, which is sometimes referred to as a placebo. The study will last for 18 months, during which time various aspects of bone health will be monitored. This includes looking at changes in bone density, which is a measure of how strong the bones are, and checking for any fractures that might occur. The study will also examine other factors related to bone health, such as bone structure and the levels of certain substances in the blood that are important for bone health.

Throughout the study, researchers will collect information to understand how teriparatide affects bone metabolism, which is the process by which bones are formed and broken down. The study aims to provide valuable insights into whether teriparatide can be an effective treatment for improving bone health in patients with chronic kidney disease and adynamic bone disorder. Participants will be closely monitored to ensure their safety and to gather comprehensive data on the effects of the treatment.

]]>